Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
13.95
+0.02 (0.14%)
Jul 15, 2025, 9:38 AM - Market open
Edgewise Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts that cover Edgewise Therapeutics stock have a consensus rating of "Buy" and an average price target of $39.89, which forecasts a 185.95% increase in the stock price over the next year. The lowest target is $14 and the highest is $51.
Price Target: $39.89 (+185.95%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Edgewise Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 5 | 6 | 5 | 5 | 5 | 5 |
| Hold | 1 | 1 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $42 | Strong Buy | Initiates | $42 | +201.08% | Jun 30, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $48 | Buy | Reiterates | $48 | +244.09% | Jun 5, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $52 → $48 | Buy | Maintains | $52 → $48 | +244.09% | May 9, 2025 |
| Wedbush | Wedbush | Buy Maintains $43 | Buy | Maintains | $43 | +208.24% | Apr 21, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $56 → $52 | Buy | Maintains | $56 → $52 | +272.76% | Apr 3, 2025 |
Financial Forecast
Revenue This Year
n/a
from 526.03M
Revenue Next Year
n/a
EPS This Year
-1.79
from -1.45
EPS Next Year
-2.04
from -1.79
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 26.3M | 76.8M | ||
| Avg | n/a | 2.8M | 31.8M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 2,611.5% | ||
| Avg | - | - | 1,022.3% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.64 | -1.51 | -1.31 | ||
| Avg | -1.79 | -2.04 | -2.00 | ||
| Low | -1.91 | -2.30 | -2.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.